Work

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM

Year: 2019

Type: article

Authors: Mayer Fishman, Janice P. Dutcher, J Clark, A. Alva, Gerald Miletello, B. Curti, Neeraj Agarwal, R. J. Hauke, Kathleen M. Mahoney, Hee Lee Moon, Jonathan Treisman, Scott S. Tykodi, Gloria Daniels, Michael A. Morse, Mabel Wong, Howard L. Kaufman, Nancy Gregory, David F. McDermott

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2980273054

FWCI: 0.927

Cites:

Cited by: 5

Related to: 10